Safety Profiles of Biological Therapies Used in Asthma Treatment

arslan, bahar; Yilmaz, Insu; ÇETİN, gülden

doi:10.21911/aai.091

Safety Profiles of Biological Therapies Used in Asthma Treatment

Gülden PAÇACI ÇETİN, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Bölümü, Kayseri, Türkiye)

Bahar ARSLAN, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Bölümü, Kayseri, Türkiye)

İnsu YILMAZ (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Bölümü, Kayseri, Türkiye)

Astım Allerji İmmünoloji

14 2

Yıl: 2022 Cilt: 20 Sayı: 3 Sayfa Aralığı: 127 - 141 Metin Dili: İngilizce DOI: 10.21911/aai.091 İndeks Tarihi: 03-05-2023

Safety Profiles of Biological Therapies Used in Asthma Treatment

Öz:

The reliability of the biologics used in the treatment of severe asthma is as important as their effectiveness. There are currently six mAbs approved for the treatment of severe asthma (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab). In this review, the safety data obtained from clinical phase studies and real-life studies of these biologics are presented in detail together with our clinical experience. More real-life studies have been done with omalizumab and mepolizumab. It has been shown in these studies that their reliability profiles are quite good. A real-life study with tezepelumab has not been published so far. There are few real-life studies on benralizumab, dupilumab, and reslizumab. However, safety profiles in RCTs with these biologics have been reported similar to placebo. In clinical phase studies, it is seen that the safety profiles of all six biological treatments are quite good.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Safety of Medicines: A guide to detecting and reporting adverse drug reactions. World Health Organization, 2002.
2. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet (London, England) 2000;356(9237):1255-9.
3. Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions: Implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring. Drug Saf 2013;36(3):147-53.
4. Ferner RE, Aronson JK. Clarification of terminology in medication errors: Definitions and classification. Drug Saf 2006;29(11):1011-22.
5. Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opin Drug Saf 2019;18(12):1161-70.
6. Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90.
8. Adachi M, Kozawa M, Yoshisue H, Lee Milligan K, Nagasaki M, Sasajima T, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term postmarketing study in Japan. Respir Med 2018;141:56-63.
9. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review. Ches 2011;139(1):28-35.
10. Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: Systematic review. Allergy 2016;71(5):593-610.
11. Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med 2017;130:55-60.
12. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 2019;7(1):156- 64.e1.
13. Baker DL, Nakamura GR, Lowman HB, Fischer SK. Evaluation of IgE antibodies to omalizumab (Xolair®) and their potential correlation to anaphylaxis. AAPS J 2016;18(1):115-23.
14. Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol 2016;138(3):913-5.e2.
15. Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA. Geohelminth infections: A review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 2008;63(4):409-17.
16. Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy 2012;5:1-9.
17. Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol 2017;139(5):1489-95.e5.
18. Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Jr., Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135(2):407-12.
19. Türk M, Bahçecioğlu SN, Tutar N. Omalizumab treatment for atopic severe persistant asthma: A single-center, long-term, reallife experience with 38 patients. Turk Thorac J 2018;19(4):187- 92.
20. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet (London, England) 2012;380(9842):651-9.
21. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, doubleblind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5(5):390-400.
22. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase IIIb Study. Clin Ther 2016;38(9):2058-70.e1.
23. Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: The COSMEX study. Clin Ther 2019;41(10):2041-56.e5.
24. Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019;143(5):1742-51.e7.
25. Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. J Clin Epidemiol 2010;63(10):1053-8.
26. Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. Pulm Pharmacol Ther 2018;53:1-5.
27. Strauss RA, Jawhari N. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field. Ann Allergy Asthma Immunol 2018;121(1):121-3.
28. Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther 2019;58:101836.
29. Lombardi C, Bagnasco D, Caruso C, D’Amato M, Menzella F, Milanese M, et al. Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulm Pharmacol Ther 2019;54:87-9.
30. Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma 2021;58(1):79-84.
31. Kasuya A, Kitano S, Hoshino T, Ishibe JI, Imura K, Goto H, et al. Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab. J Dermatol 2019;46(9):e309-e11.
32. Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol 2019;144(5):1336-42.e7.
33. Yilmaz I, Türk M, Nazik Bahçecioğlu S, Tutar N, Gülmez I. Efficacy of mepolizumab treatment in oral corticosteroiddependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: Single center, real life study. Turk J Med Sci 2020;50(2):433-41.
34. Nazik Bahçecioğlu S, Türk M, Atayık E, Pacacı Çetin G, Arslan B, Gülmez İ, et al. Mepolizumab-related adverse events in severe eosinophilic asthma: A real-life study. Asthma Allergy Immunol 2022;20:81-6.
34. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebocontrolled, phase 3 trials. Lancet Respir Med 2015;3(5):355-66.
35. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 study. Chest 2016;150(4):789-98.
36. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125-32.
37. Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: A review. Drugs 2017;77(7):777-84.
38. Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: Focus on reslizumab. Expert Opin Drug Saf 2018;17(4):429-35.
39. Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 2017;5(6):1572-81.e3.
40. Ibrahim H, O’Sullivan R, Casey D, Murphy J, MacSharry J, Plant B, et al. The effectiveness of Reslizumab in severe asthma treatment: A real-world experience. Respir Res 2019;20(1):1-5.
41. de Llano LAP, Cosío BG, Astiárraga IL, Campos GS, Alonso MÁT, Malanda NM, et al. Asthma control in patients with severe eosinophilic asthma treated with reslizumab: Spanish real-life data. J Asthma Allergy 2022;15:79-88.
42. Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, et al. Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest 2021;159(5):1734-46.
43. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England) 2016;388(10056):2115-27.
44. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 2016;388(10056):2128-41.
45. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376(25):2448-58.
46. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019;7(1):46-59.
47. Miralles López JC, Escudero Pastor AI, Carbonell Martínez A, Navarro Garrido C, Bonilla Pacheco Y, Petrik Petrik Y. Benralizumab in real life. J Investig Allergol Clin Immunol 2021;31(1):87-8.
48. Padilla-Galo A, Levy-Abitbol R, Olveira C, Valencia Azcona B, Pérez Morales M, Rivas-Ruiz F, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med 2020;20(1):184. 49. Xiong XF, Zhu M, Wu HX, Fan LL, Cheng DY. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: A meta-analysis of randomized clinical trials. Respir Res 2019;20(1):108.
50. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet (London, England) 2016;388(10039):31-44.
51. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378(26):2475-85.
52. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378(26):2486-96.
53. Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy 2020;50(7):789-798.
54. Touhouche AT, Cassagne M, Bérard E, Giordano-Labadie F, Didier A, Fournié P, et al. Incidence and risk factors for dupilumab associated ocular adverse events: A real-life prospective study. J Eur Acad Dermatol Venereol 2021;35(1):172-9.
55. Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9(11):1299-312.
56. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021;384(19):1800-9.
57. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017;377(10):936-46.

APA	ÇETİN g, arslan b, Yilmaz I (2022). Safety Profiles of Biological Therapies Used in Asthma Treatment. , 127 - 141. 10.21911/aai.091
Chicago	ÇETİN gülden,arslan bahar,Yilmaz Insu Safety Profiles of Biological Therapies Used in Asthma Treatment. (2022): 127 - 141. 10.21911/aai.091
MLA	ÇETİN gülden,arslan bahar,Yilmaz Insu Safety Profiles of Biological Therapies Used in Asthma Treatment. , 2022, ss.127 - 141. 10.21911/aai.091
AMA	ÇETİN g,arslan b,Yilmaz I Safety Profiles of Biological Therapies Used in Asthma Treatment. . 2022; 127 - 141. 10.21911/aai.091
Vancouver	ÇETİN g,arslan b,Yilmaz I Safety Profiles of Biological Therapies Used in Asthma Treatment. . 2022; 127 - 141. 10.21911/aai.091
IEEE	ÇETİN g,arslan b,Yilmaz I "Safety Profiles of Biological Therapies Used in Asthma Treatment." , ss.127 - 141, 2022. 10.21911/aai.091
ISNAD	ÇETİN, gülden vd. "Safety Profiles of Biological Therapies Used in Asthma Treatment". (2022), 127-141. https://doi.org/10.21911/aai.091

APA	ÇETİN g, arslan b, Yilmaz I (2022). Safety Profiles of Biological Therapies Used in Asthma Treatment. Astım Allerji İmmünoloji, 20(3), 127 - 141. 10.21911/aai.091
Chicago	ÇETİN gülden,arslan bahar,Yilmaz Insu Safety Profiles of Biological Therapies Used in Asthma Treatment. Astım Allerji İmmünoloji 20, no.3 (2022): 127 - 141. 10.21911/aai.091
MLA	ÇETİN gülden,arslan bahar,Yilmaz Insu Safety Profiles of Biological Therapies Used in Asthma Treatment. Astım Allerji İmmünoloji, vol.20, no.3, 2022, ss.127 - 141. 10.21911/aai.091
AMA	ÇETİN g,arslan b,Yilmaz I Safety Profiles of Biological Therapies Used in Asthma Treatment. Astım Allerji İmmünoloji. 2022; 20(3): 127 - 141. 10.21911/aai.091
Vancouver	ÇETİN g,arslan b,Yilmaz I Safety Profiles of Biological Therapies Used in Asthma Treatment. Astım Allerji İmmünoloji. 2022; 20(3): 127 - 141. 10.21911/aai.091
IEEE	ÇETİN g,arslan b,Yilmaz I "Safety Profiles of Biological Therapies Used in Asthma Treatment." Astım Allerji İmmünoloji, 20, ss.127 - 141, 2022. 10.21911/aai.091
ISNAD	ÇETİN, gülden vd. "Safety Profiles of Biological Therapies Used in Asthma Treatment". Astım Allerji İmmünoloji 20/3 (2022), 127-141. https://doi.org/10.21911/aai.091